REFERENCES
- Hitchings, GH. The utilization of biochemical differ-ences between host and parasite as a basis for chemotherapy. In: Goodwin LE, Nurino-Smith RH ( Eds). Drugs, parasites, and hosts. Churchill, London, 1962: 196-210.
- Brumfitt W, Hamilton-Miller JMT. Co-trimoxazole or trimetoprim alone? A viewpoint on their relative place in therapy. Drugs 1982; 24: 453–458.
- British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, 5.1.8. Sulphonamides and trimethoprim, Number 25 (March 1993), 1993: 227-228.
- Reeves D. Good antimicrobial prescribing. Sulphonamides and trimetoprim. Lancet 1982; August 14: 370-373.
- Kucers A, Bennett NMcK, Kemp RJ. Trimethoprim, co-trimoxazole (Co-T) and other trimethoprim combinations. In: The use of antibiotics, Fourth ed., William Heinemann Medical Books, London, 1987: 1118-1202.
- Braunsteiner AR, Fisinger F. Brodimoprim: therapeutic efficacy and safety in the treatment of bacterial infections. J Chemother 1993; 5: 153–157.
- Brumfitt W, Hamilton-Miller JMT. Reassessment of the rationale for the combinations of sulfonamides with diaminopyrimidines. J Chemother 1993; 5: 111–120.
- Sande MA, Kapusnik-Uner JE, Mandell GL. Antimicrobial agents; trimethoprim-sulfamethoxazole. In: The Pharmacological Basis of Therapeutics, eighth ed. (Goodman Gilman A, Rail TW, Nies AS, Taylor P, eds), Pergamon Press, New York, 1990: 1054-1057.
- Avery GS. Trimethoprim-sulphamethoxazole: a review. Drugs 1971; 1: 7–53.
- Bushby SRM. Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J Infect Dis 1973; 128 (Suppl): 442-462.
- Hitchings GH. Biochemical background of trimetho-prim-sulfamethoxazole. Med J Australia 1973; 1 (Suppl): 5-9.
- Wormser GP, Keusch GT, Hell RC. Co-trimoxazole (trimethoprim-sulfamethoxazole). An update review of its antibacterial activity and clinical efficacy. Drugs 1982; 24: 459–518.
- Then RL, Hermann F. Properties of brodimoprim as an inhibitor of dihydrofolate reductase. Chemotherapy 1984; 30: 18–25.
- Hartman PG. Molcular aspects and mechanism of action of dihydrofolate reductase inhibitors. J Chemother 1993; 5: 17–24.
- Amyes SGB. Comparative antibacterial spectrum of trimethoprim and brodimoprim. J Chemother 1993: 5: 63–67.
- Benoit-Lemercier C, Bergogne-Berezin E, Joly-Guillou ML. In vitro brodimoprim activity on bacterial strains. J Chemother 1993; 5: 81–92.
- Amyes SGB, Towner KJ. Trimethoprim resistance: epi-demiology and molecular aspects. J Med Microbiol 1990; 31: 1–19.
- Goldstein FW, Acar JG. Epidemiology of resistance to diaminopyrimidines. J Chemother 1993; 5: 99–103.
- Thomson CJ. Trimethoprim and brodimoprim resis-tance of Gram-positive and Gram-negative bacteria. J Chemother 1993; 5: 104–110.
- Periti P, Mazzei T, Mini E, Novelli A. Brodimoprim, farmacologia clinica e chemioterapia. Farm Ter 1993; Suppl 1: 5-80.
- Stephan-Giildner M. Preclinical toxicology and safety pharmacology of brodimoprim in comparison to trimetoprim and analogs. J Chemother 1993; 5: 48–57.
- Salmi HA. Brodimoprim in acute respiratory tract infections. J Chemother 1993; 5: 532–536.